{
  "report_rows": [
    {
      "kpi": "Q2 2026 operating EPS",
      "prediction": "BEAT",
      "answer": "pred ~$3.72 vs. cons $3.67",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.60B vs. cons $1.59B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 United American health underwriting margin",
      "prediction": "BEAT",
      "answer": "pred ~$23M vs. cons $21M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Operating EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$15.75 midpoint vs. cons $15.69 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Life-assumption update pretax benefit",
      "prediction": "UNCHANGED",
      "answer": "guide ~$90M midpoint vs. cons $90M (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health premium growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~15.5% midpoint vs. cons 15.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "American Income average producing agent growth",
      "prediction": "LOWER",
      "answer": "guide ~1% vs. cons 2% (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.6,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.7,
  "day5_path": "FADE",
  "day5_rationale": "A modest EPS beat and Medicare Supplement margin recovery support the initial move, but an unchanged Q3 assumption benefit and weaker American Income agent growth limit out-period estimate revisions; elevated valuation and less accretive repurchases at the higher share price drive a partial fade.",
  "day5_confidence": "MEDIUM"
}